沙立度胺单独及联合多柔比星对人肝癌细胞株HepG2中生存素表达的影响  

The Effects of Thalidomide Alone and Combined with Doxorubicin on Survivin Expression in Human Hepatoma HepG2 Cell Lines

作　　者：韩亚光[1] 崔彦芝[2] 付华斌[1] 曹世堂[1] 陈京莲[1] 何翠[1] 

机构地区：[1]解放军白求恩国际和平医院256临床部内科,河北正定050800 [2]南方医科大学南方医院肿瘤中心,广州510515

出　　处：《华北国防医药》2008年第5期60-62,F0002,共4页Medical Journal of Beijing Military Region

摘　　要：目的:观察沙立度胺单独及联合多柔比星对人肝癌细胞株HepG2中生存素(Survivin)表达的影响。方法:常规培养人肝癌细胞株HepG2随机分成4组:空白对照组;多柔比星组(1.0 mg/L);沙立度胺组(50、100、200、400 mg/mL,4个对半稀释质量浓度);联合用药组:沙立度胺(200 mg/mL)+多柔比星(1.0 mg/L)。分别对HepG2细胞作用12、24、48、72 h后,应用免疫组织化学法观察对Survivin表达的影响。结果:沙立度胺单独及联合多柔比星作用于HepG2细胞可下调Survivin表达,单药沙立度胺以200 mg/L作用48 h效果最为明显,联合用药组下调Survivin表达优于其余各组,差异有统计学意义(P<0.05)。结论:沙立度胺可下调人肝癌细胞株HepG2 Survivin的表达,且与多柔比星有协同作用,可能是沙立度胺抗肿瘤机制之一。Objective：To investigate the effects of Thalidomide alone and combined with Doxorubicin on Survivin expression in human hepatoma cell lines HepG2 in vitro. Methods： Human hepatoma cell lines HepG2 cultivated by convention, were randomly divided into 4 groups ： untreated control group ; Doxorubicin group（ 1.0 mg/L） ; Thalidomide group （ 50,100,200,400 mg/mL） ; drug combination group （Thalidomide 200 mg/mL ＋ Doxorubicin 1.0 mg/L）. After H epG2 was treated for 12,24,48,72 hours as described above, the effects on Survivin expression were studied by immunocytoehemistry. Results：The results of immunocytochemieal technique showed that the expression of Survivin of Thalidomide group and combination group were down-regulated in vitro contrast with that of untreated control group. The strongest inhibition effect was seen after treating HepG2 cell lines 48 hours with 200 mg/L among Thalidomide alone group. Combination group showed better inhibition effect on HepG2 cell lines than other groups （ P 〈 0.05 ）. Conclusion： Thalidomide can decrease Survivin expression in HepG2 cell lines in vitro,which may be one of the possible molecular anti-tumor mechanisms of thalidomide.

关 键 词：沙立度胺 多柔比星 肝肿瘤 HEPG2 生存素 基因表达调控 肿瘤 

分 类 号：R735.7[医药卫生—肿瘤]